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Targeted metabolomics analysis 
of postoperative delirium
Bridget A. Tripp1,2*, Simon T. Dillon3,4,6, Min Yuan5, John M. Asara4,5, 
Sarinnapha M. Vasunilashorn4,6,7, Tamara G. Fong4,8,9, Eran D. Metzger10,11, 
Sharon K. Inouye4,6,9, Zhongcong Xie4,12, Long H. Ngo4,6,7, Edward R. Marcantonio4,6,13, 
Towia A. Libermann3,4,6,13 & Hasan H. Otu1,13
Postoperative delirium is the most common complication among older adults undergoing major 
surgery. The pathophysiology of delirium is poorly understood, and no blood-based, predictive 
markers are available. We characterized the plasma metabolome of 52 delirium cases and 52 
matched controls from the Successful Aging after Elective Surgery (SAGES) cohort (N = 560) of 
patients ≥ 70 years old without dementia undergoing scheduled major non-cardiac surgery. We applied 
targeted mass spectrometry with internal standards and pooled controls using a nested matched 
case-control study preoperatively (PREOP) and on postoperative day 2 (POD2) to identify potential 
delirium risk and disease markers. Univariate analyses identified 37 PREOP and 53 POD2 metabolites 
associated with delirium and multivariate analyses achieved significant separation between the two 
groups with an 11-metabolite prediction model at PREOP (AUC = 83.80%). Systems biology analysis 
using the metabolites with differential concentrations rendered “valine, leucine, and isoleucine 
biosynthesis” at PREOP and “citrate cycle” at POD2 as the most significantly enriched pathways (false 
discovery rate < 0.05). Perturbations in energy metabolism and amino acid synthesis pathways may be 
associated with postoperative delirium and suggest potential mechanisms for delirium pathogenesis. 
Our results could lead to the development of a metabolomic delirium predictor.
Delirium is a condition characterized by an acute change and fluctuation in attention, thinking, and conscious-
ness. Postoperative delirium complicates the courses of 15–53% of older adults undergoing major surgical 
 procedures1,2, and is associated with higher rates of postoperative  complications3, longer hospital  stays4, higher 
rates of discharge to extended care  facilities5, and increased  mortality4–6. The economic impact of delirium 
associated health care expenditures is over $164 billion per year in the U.S.  alone7.
Currently, delirium is solely a clinical diagnosis, and there is no laboratory test or biomarker to facilitate 
its diagnosis. Additionally, delirium etiology and pathogenesis are poorly understood. Previous research has 
suggested several mechanisms for delirium pathogenesis, which include: (1) increased expression of inflam-
matory markers found in the blood and central nervous  system8–12; (2) alterations in plasma levels of precur-
sor amino acids leading to dysfunction in neurotransmitter  systems13; (3) oxidative stress leading to cerebral 
 dysfunction14–16; (4) acute or chronic stress response resulting in aberrantly high levels of  glucocorticoids17,18; 
and (5) dysregulation of the circadian  rhythm15,19–21.
Metabolomics is a high-throughput quantitative approach to study the metabolome—the collection of small 
metabolites found in a system. These smaller metabolic molecules are often the end products of the biochemical 
processes in a cell and are particularly sensitive to endogenous and exogenous  stimuli22. Differences in their con-
centration levels provide an efficient way to monitor and detect alterations in specific cellular pathways. Metabo-
lomics can reveal transient biochemical changes that are closely aligned with the disease state of a  system22.
OPEN
1Department of Electrical and Computer Engineering, University of Nebraska-Lincoln, Nebraska Hall E419, 
P.O. Box 880511, Lincoln, NE 68588, USA. 2PhD Program of Complex Biosystems, University of Nebraska-Lincoln, 
Lincoln, USA. 3Proteomics, Bioinformatics and Systems Biology Center, Beth Israel Deaconess Medical Center, 
Boston, USA. 4Harvard Medical School, Boston, USA. 5Division of Signal Transduction and Mass Spectrometry 
Core, Beth Israel Deaconess Medical Center, Boston, USA. 6Department of Medicine, Beth Israel Deaconess 
Medical Center, Boston, USA. 7Harvard T.H. Chan School of Public Health, Boston, USA. 8Department of Neurology, 
Beth Israel Deaconess Medical Center, Boston, USA. 9Aging Brain Center, Marcus Institute for Aging Research, 
Hebrew SeniorLife, Boston, USA. 10Department of Medicine, Hebrew SeniorLife, Boston, USA. 11Department of 
Psychiatry, Beth Israel Deaconess Medical Center, Boston, USA. 12Department of Anesthesia, Critical Care and Pain 
Medicine, Massachusetts General Hospital, Boston, USA. 13These authors jointly supervised this work: Edward 
R. Marcantonio, Towia A. Libermann and Hasan H. Otu. *email: bridget.tripp@huskers.unl.edu
2
Vol:.(1234567890)
Scientific Reports |         (2021) 11:1521  | https://doi.org/10.1038/s41598-020-80412-z
www.nature.com/scientificreports/
Metabolomics has been extensively used to characterize cellular changes in disease phenotypes and facilitate 
identification of disease-specific  markers23–25. Targeted metabolomics approaches have been employed previ-
ously in identifying novel biomarkers and distinguishing between diseased and healthy  cohorts26,27. Only a few 
prior studies have explored metabolic changes associated with delirium and illuminating potential underlying 
biological  mechanisms28–31.
To obtain more insights into the pathophysiological mechanisms of delirium as well as to identify potential 
risk and disease markers, we performed targeted metabolomic profiling both at preoperative and postoperative 
time points. We identified multiple metabolites linked to delirium before and after surgery and demonstrated 
enrichment of several metabolic pathways. Our associative, predictive, and systems analysis may help to identify 
pathophysiologic pathways to prioritize for development of diagnostic and therapeutic regimens for postopera-
tive delirium.
Results
In Fig. 1, we show the overall workflow of the experimental and computational steps applied in this paper.
Sample characteristics. Table  1 shows the sample demographics and clinical variables of the metabo-
lomics patient samples. On average, patients in the matched sample (n = 104; 52 matched pairs) were 77 years 
old, 53% female, and 49% had a vascular comorbidity. The characteristics of the delirium cases (DEL) and no-
delirium controls (CNT) were similar, indicating a successful match procedure. In terms of non-match variables, 
on average both cases and control were overweight and showed little evidence of malnutrition. Both cases and 
controls reported poor sleep in the hospital, which is  typical32, with cases experiencing slightly more sleep dis-
ruption. The prevalence of diabetes medication use was low and similar in cases and controls. We did not control 
for the variables that were not used in the matching process because of the risk of over-controlling for variables 
that are potentially along the causal pathway to  delirium33,34.
Data pre-processing. We identified 250 metabolites as “present,” i.e., detected at a level suitable for down-
stream analysis (out of 315 metabolites measured). Missing data accounted for 3.15% of total data acquired from 
present metabolites (Supplementary Table S1), which was much smaller than the typical amount of missing 
data percentage seen in metabolomics studies (15–26%)35–39. After data imputation, signal drift correction, and 
normalization, the percent relative standard deviation (RSD) was less than 5 for 87% and less than 10 for 98% of 
all metabolites in the pooled QC samples (Supplementary Tables S2, S3, S4).
Metabolites altered in delirium group at PREOP. Thirty-seven metabolites were found to be altered 
in DEL at PREOP (nominal p value < 0.05 in at least two tests) when compared with CNT (Fig. 2a; Table 2a; 
Table 1.  Sample characteristics in the matched cohorts. 1 Variable used for matching. 2 Full sample N = 85 
(delirium n = 39, no delirium n = 46). 3 Full sample N = 34 (delirium n = 15, no delirium n = 19); albumin 
was tested only when malnutrition was suspected. 4 Positive response to question on either POD1 or POD2; 
Sample for this question: N = 100 (delirium n = 48, no delirium n = 52). 5 Sample for this question: N = 82 
(delirium n = 43, No delirium n = 39). Abbreviations: ApoE  =  Apolipoprotein E, GCP  =  general cognitive 
performance, M  =  mean, 3MS  =  Modified Mini-Mental State Examination, SD  =  standard deviation, PREOP 
=  preoperative, POD  =  postoperative day.
Study variables
Full sample Delirium No delirium
(N = 104) (N = 52) (N = 52)
Age (M, SD)1 77.1 (4.7) 77.3 (5.0) 77.0 (4.4)
Female (%)1 56 (53%) 28 (55%) 28 (55%)
Nonwhite, n (%) 10 (9%) 5 (9%) 5 (9%)
Education in years (M, SD) 15.0 (2.8) 15.0 (3.0) 15.1 (2.7)
GCP (M, SD)1 55.6 (5.4) 55.2 (5.5) 56.0 (5.4)
Charlson score (M, SD) 1.3 (1.4) 1.3 (1.4) 1.3 (1.5)
Vascular comorbidity, n (%)1 52 (49%) 26 (49%) 26 (49%)
ApoE ɛ4 carrier, n (%)1 24 (23%) 12 (23%) 12 (24%)
Anesthesia type, n (%)
General 85 (83%) 42 (82%) 43 (84%)
Spinal 17 (17%) 9 (18%) 8 (16%)
Both 0 (0%) 0 (0%) 0 (0%)
PREOP body mass index (M, SD) 29.0 (4.9) 29.9 (5.5) 28.2 (4.1)
Unintentional weight loss in past year (≥ 10 lbs)2 7 (8%) 2 (5%) 5 (11%)
PREOP albumin (g/dL, M, SD)3 4.3 (0.4) 4.4 (0.4) 4.2 (0.4)
Any problems with sleep in the past night, n (%)4 83 (83%) 44 (92%) 39 (75%)
In-hospital sleep problem is new or worse, n (%)5 72 (88%) 39 (91%) 33 (85%)
Taking diabetes medication on admission 17 (16%) 8 (15%) 9 (17%)
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Supplementary Table S5). Four of these metabolites had a binomial test BH-corrected p value < 0.05: trehalose-
6-phosphate, phenyllactic acid, creatine, and N-acetyl-l-alanine. We performed 10,000 tenfold splits where at 
each iteration 1/10th of the samples were left out in each group, and the three statistical tests were run on the 
remaining samples. Twenty-eight of the thirty-seven metabolites had a nominal p value < 0.05 in at least two tests 
more than 50% of the time, thus showing high robustness (Supplementary Table S6).
Applying one predictive and one orthogonal component, the OPLS-DA model produced moderate separa-
tion between PREOP DEL and CNT, and minimal within group variation (Fig. 2c). Despite the good separation 
achieved in Fig. 2c, and high total sum of variation explained by the model (R2Y(cum) = 0.719), the estimation of 
model predictive performance was modest (Q2 = 0.203). Variable importance in projection (VIP) scores, which 
reflect both the loading weights and variability of response, bolstered previous univariate findings (Table 2a; 
Fig. 2e). The OPLS-DA model was initially validated using permutation testing and further tested for robustness 
by CV-ANOVA. The p values for permutation testing were pR2Y < 0.159 and pQ2 < 0.001, and for CV-ANOVA 
was < 2.4E−4, thus showing a statistically significant validation of the separation achieved between PREOP DEL 
and CNT when using this model. There were 11 metabolites with a VIP score > 2.0 (VIP > 1.0 is considered sig-
nificant in distinguishing between classes), which included three of the four metabolites that showed a binomial 
test BH-corrected p value < 0.05. A support vector machine (SVM) prediction  model40 using these 11 metabolites 
as predictors yielded an area under the curve (AUC) of 83.80% for the associated receiver operating characteristic 
(ROC) curve (Supplementary Fig. S2).
Metabolites altered in delirium group at POD2. Fifty-three metabolites were found to have had sig-
nificantly different concentrations between DEL and CNT at POD2 with a BH p value < 0.05 in at least two tests 
(Fig. 2b; Table 2b; Supplementary Table S7). Six of these metabolites were also altered at PREOP with three of 
them reversing the FC directionality. PREOP and POD2 associated metabolites represent candidate risk and 
disease markers, respectively. Therefore, the metabolites and/or their FC sign may be different because they rep-
resent different underlying biological mechanisms. Based on the 10,000 tenfold cross validation split datasets, all 
of the metabolites had p < 0.05 in at least two tests in all of the cases, and 28 of the metabolites had BH-corrected 
p < 0.05 in at least two tests in more than 50% of the cases (Supplementary Table S6).
Using one predictive and two orthogonal components, the OPLS-DA model produced clear separation 
between POD2 DEL and CNT with R2Y(cum) = 0.848 and predictive performance with R2Q = 0.344 (Fig. 2d,f). 
All VIP scores were at or above 1.0, supporting univariate findings (Table 2b; Fig. 2). The model was validated 
using permutation testing and evaluated for robustness with CV-ANOVA. The p values for permutation testing 
were pR2Y < 0.004 and pQ2 < 0.001, and for CV-ANOVA it was < 9.0E−7. These results support a statistically 
significant separation achieved between POD2 DEL and CNT when using this model. Based on both the sta-
tistical analysis and predictive modeling, metabolites at POD2 show significantly better discriminative power 
than at PREOP.
Figure 1.  Experimental design workflow. Key steps in our experimental design included: sample preparation, 
mass spectrometric qualitative and quantitative analysis, data preprocessing, univariate and multivariate 








Metabolites VIP AVGp FC Metabolites VIP AVGp FC
Trehalose-6-phosphate3 2.51 7.6E−04 1.52 Proline3 2.78 0.02 1.26
Phenyllactic acid 1.94 1.1E−03 − 1.19 N-acetyl-glutamate3 2.20 0.02 − 1.03
Creatine3 2.46 1.2E−03 − 1.36 Homocysteic acid 1.40 0.02 1.00
N-Acetyl-l-alanine3 2.49 1.3E−03 − 1.37 Dimethylglycine 1.86 0.02 − 1.22
S-Methyl-5-thioadenosine1,2 1.56 3.5E−03 − 1.47 Uridine3 2.42 0.02 − 1.10
Uracil3 2.84 4.2E−03 − 1.32 d-glyceraldehdye-3-phosphate 1.23 0.02 − 1.22
2-Oxobutanoate1,2,3 2.38 4.4E−03 − 1.08 Cytidine1 1.30 0.02 0.77
5-Methyl-THF 1.85 0.01 − 1.16 Glycolate 1.54 0.02 − 1.33
3-Hydroxybuterate3 2.56 0.01 − 1.69 N-Acetyl-glucosamine1 1.40 0.03 1.34
Allantoin 1.78 0.01 1.01 dl-Pipecolic acid 1.12 0.03 − 0.94
Citrulline 1.54 0.01 0.86 l-Isoleucine_15N 1.37 0.03 − 1.25
Creatinine3 2.11 0.01 − 1.02 d-gluconate 1.48 0.03 0.92
dTDP 0.58 0.01 − 1.37 Folate 1.31 0.03 − 1.05
Pyridoxine 1.41 0.01 − 1.19 Xanthine 1.44 0.04 − 0.68
S-Ribosyl-l-homocysteine1,2 1.66 0.01 − 0.86 Isoleucine 1.15 0.04 − 1.12
Glucono-delta-lactone1 1.90 0.01 1.19 Nicotinamide ribotide 0.95 0.05 − 0.83
FAD 1.78 0.01 1.04 Nicotinamide3 2.11 0.05 − 0.66
Valine 1.05 0.02 − 1.30 Nicotinamide Riboside 1.08 0.07 0.74
Dehydroascorbic acid 1.88 0.02 − 1.02
b 
Postoperative Day 2 (POD2)
Metabolites VIP AVGp FC Metabolites VIP AVGp FC
p-Hydroxybenzoate 1.96 1.1E−04 2.05 Aconitate 1.33 0.02 1.43
Citrate 2.02 2.5E−04 1.25 Kynurenic acid 1.34 0.03 1.45
Acetoacetate 2.25 7.5E−04 1.54 S-Ribosyl-l-homocysteine1 1.28 0.03 1.11
Citraconic acid/itaconic  acid4 2.01 1.0E−03 1.38 Ascorbic acid 1.63 0.03 − 0.94
Itaconic acid 1.96 1.0E−03 1.37 Maleic acid 1.44 0.03 1.36
2-Ketohexanoic acid 1.65 1.2E−03 1.46 Orotate 1.21 0.03 1.37
Deoxyinosine 2.09 1.4E−03 1.90 Atrolactic acid 1.53 0.03 1.28
N-acetyl-glucosamine 2.07 1.6E−03 1.41 Fumarate 1.41 0.03 1.30
Myo-inositol 1.97 2.0E−03 1.27 Xanthurenic acid 1.61 0.03 − 1.21
Isocitrate 1.91 2.1E−03 1.52 2-Keto-isovalerate 1.36 0.03 1.36
5-Phosphoribosyl-1-pyrophosphate 1.68 2.5E−03 1.45 Glutathione disulfide 1.75 0.03 1.28
dAMP 1.73 4.0E−03 1.56 Glycerophospho-choline 1.00 0.03 − 1.50
2-Hydroxy-2-methylbutanedioic acid 1.78 4.5E−03 1.38 d-Glucono-delta-lactone-6-phosphate 1.75 0.03 0.81
3-S-Methylthiopropionate 1.43 4.6E−03 1.82 S-Methyl-5-thioadenosine 1.19 0.03 1.00
Ng,NG-dimethyl-l-arginine 2.13 0.01 1.10 SBP 1.44 0.03 1.10
Citrate-isocitrate 1.57 0.01 1.23 S-Adenosyl-l-homocysteine 1.86 0.03 1.02
Cytidine1 2.07 0.01 1.57 d-Sedoheptulose-1-7-phosphate 1.31 0.03 1.06
1-Methyladenosine 1.88 0.01 1.55 Glucono-delta-lactone 1.43 0.03 0.74
GTP 1.82 0.01 1.56 Acetylphosphate 1.48 0.04 1.23
d-Gluconate 1.64 0.01 0.99 α-Ketoglutarate 1.72 0.04 1.26
4-Phosphopantothenate 1.57 0.01 1.60 Oxaloacetate 1.09 0.04 1.43
Dihydroorotate 1.32 0.01 1.22 2-Oxobutanoate 1.02 0.04 1.10
Glyoxylate 1.25 0.02 1.45 1-Methyl-Histidine 1.38 0.04 0.97
O8P-O1P 1.61 0.02 1.28 Homocysteine 1.78 0.04 1.66
d-Glucarate1 1.62 0.02 1.11 dUMP 1.11 0.04 0.72
Acetyllysine 1.31 0.02 1.54 Glucosamine 1.58 0.04 1.57
S-Adenosyl-l-methionine 1.62 0.02 1.48
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Pathway enrichment analysis. At PREOP, the valine, leucine, and isoleucine biosynthesis pathway was 
the most significantly enriched (FDR < 0.04) (Table 3a; Supplementary Table S8; Supplementary Fig. S3). This 
canonical pathway is found in many species but the metabolic reactions specific to humans are noted by dashed 
boxes in Fig.  3a. These four reactions require the enzyme serine dehydratase or branched chain amino acid 
 aminotransferase41–43. These chemical processes include eight metabolites, and of these, three of them were 
found to have significant differential concentrations (nominal p value < 0.05) at PREOP: 2-oxobutanoate, isoleu-
cine, and valine. All three metabolites were downregulated in DEL (Fig. 3a). 
At POD2, three pathways were found to be significantly enriched with our significant metabolites (N = 53) 
(Table 3b, Supplementary Table S8, Supplementary Fig. S3). The citrate cycle was the most significant pathway 
(FDR < 0.0019). This pathway included six significant metabolites which were all upregulated in DEL at POD2 
(Fig. 3b). Furthermore, in Fig. 3b we show one additional metabolite, itaconate/itaconic acid, which is increased 
in delirium cases, but is not part of the classical citrate cycle. Itaconic acid is directly linked to the metabolite 
aconitate in this pathway.
Table 2.  Metabolites with significant differential concentrations between delirium and control groups. 
Metabolites were considered significant if they passed two or more statistical tests. The AVG-p is the 
average of the p values that passed cutoff. Variable importance in projection (VIP) score was obtained from 
orthogonal partial least squares discriminant analysis (OPLS-DA). VIPs reflect both the loading weights and 
the variability of each response. Fold-change (FC) of each metabolite was calculated by applying the one-step 
Tukey’s biweight algorithm on traditionally calculated FC values (Delirium/Control) for each paired sample. A 
negative FC denotes downregulation in the delirium group. a) PREOP: 37 metabolites statistically significant 
with a nominal p value < 0.05. b) POD2: 52 metabolites statistically significant with a BH-corrected p 
value < 0.05. 1 Metabolites found to have significant differentially quantified concentrations in both PREOP and 
POD2. 2 Those metabolites with an opposite fold change directionality at each time point. 3 The 11-metabolite 
predictors used for the SVM prediction model at PREOP. 2-Oxobutanate is the only one found to be significant 
at both PREOP and POD2. 4 The selected reaction monitoring (SRM) transition for this entry allows for 
detecting both itaconic acid and citraconic acid and is not specific to either. Metabolites included in this entry 
do not chemically behave as expected under the individual itaconic acid SRM, or the itaconic acid entry would 
have captured them.
Table 3.  Biochemical pathways enriched with significant metabolites at preoperative (PREOP) and 
postoperative day 2 (POD2). Enriched pathways (p < 0.05) were identified using MetaboAnalyst 4.081–83, which 
considers both metabolite over representation within a pathway and location  importance41,84. A metabolite was 
included in biological systems analysis if it showed significant differentially quantified concentrations (nominal 
p value < 0.05 (PREOP), Benjamini–Hochberg (BH) p value < 0.05 (POD2)) in two or more statistical tests. 
“Total” represents the number of metabolites in the pathway, while “Hits” is the number of “input” metabolites 
found in the pathway.
a
Preoperative (PREOP) Total Expected Hits Raw p FDR
Valine, leucine, and isoleucine biosynthesis 8 0.18 3 0.0005 0.04
Nicotinate and nicotinamide metabolism 15 0.33 3 0.0037 0.15
Pyrimidine metabolism 39 0.86 4 0.0092 0.26
One carbon pool by folate 9 0.20 2 0.0153 0.32
Glycine, serine, and threonine metabolism 33 0.72 3 0.0336 0.50
Arginine biosynthesis 14 0.31 2 0.0360 0.50
b
Postoperative Day 2 (POD2) Total Expected Hits Raw p FDR
Citrate cycle (TCA cycle) 20 0.65 6 2.30E−05 0.0019
Cysteine and methionine metabolism 50 1.06 6 4.70E−04 0.014
Pentose phosphate pathway 56 0.71 5 4.96E−04 0.014
Glyoxylate and dicarboxylate metabolism 32 1.03 5 0.003 0.062
Pyrimidine metabolism 39 1.26 5 0.007 0.120
Alanine, aspartate, and glutamate metabolism 28 0.90 4 0.011 0.155
Ascorbate and aldarate metabolism 8 0.26 2 0.025 0.265
Valine, leucine, and isoleucine biosynthesis 8 0.26 2 0.025 0.265
Pyruvate metabolism 22 0.71 3 0.032 0.295
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Discussion
In this paper, we applied targeted metabolomics to study delirium both pre- and postoperatively using a nested 
matched case-control design that maximizes efficiency and control of confounding factors. We identified metabo-
lites associated with delirium both at PREOP and POD2 suggesting potential risk and disease markers. Our 
11-metabolite predictive signature at PREOP, which achieved an AUC close to 84%, can be combined with 
other biomarker panels in a multi-omics approach. Systems biology analysis suggests that the ‘valine, leucine, 
and isoleucine biosynthesis’ and ‘citrate cycle’ pathways may be dysregulated in delirium. These altered pathways 
coincide with alternative energy pathways previously implicated in delirium pathogenesis in several  studies15,31,44. 
Our findings suggest that alterations in primary and secondary energy production, amino acid synthesis meta-
bolic pathways, and increased oxidative stress may be involved in the etiology and pathophysiology of delirium.
Metabolomics provides new insights into metabolic phenotypes and dysregulations of metabolic pathways 
underlying human disease and adds an important avenue for biomarker and therapeutic target discovery. How-
ever, experimental and computational challenges such as sample size, batch effect, peak drift, and data normali-
zation hamper wide-spread  use45. We established a robust workflow by using internal standards and pooled QC 
samples that provided reliable data for downstream analysis (RSD < 10% for > 98% of the metabolites in pooled 
QC samples).
Our study is one of only a few metabolomics studies of delirium. Pan et al. characterized the preoperative 
cerebrospinal fluid (CSF) metabolome of older patients (≥ 65 years) who developed delirium following elective 
hip or knee arthroplasty. They found that spermidine, putrescine, and glutamine were significantly upregulated 
in delirium patients compared to  controls30. In a blood-based metabolomics study of delirium, Guo et al. took an 
untargeted metabolomics approach in characterizing preoperative serum metabolites of older surgical patients 
(between 65 and 80 years) undergoing hemiarthroplasty for hip fractures. They identified four metabolites associ-
ated with a higher risk of postoperative delirium (S-methylcysteine, linolenic acid, eicosapentaenoic acid, and 
linoleic acid) with alterations in energy metabolism and oxidative stress  pathways29. In a follow-up study, Guo 
et al. profiled both PREOP and POD1 samples and reported imbalances between branched-chain and aromatic 
amino acids with perturbations in tricarboxylic cycle and oxidative stress  pathways31. Although the specific 
metabolites and direction of dysregulation were not always consistent within the three studies (Supplementary 
Table S9), there were agreements in perturbed pathways.
There were six metabolites found to be significant at both time points; three displayed opposite directions in 
fold change noted in Table 2. This observation could be because the significant metabolites in the two timepoints 
imply different clinical/biological mechanisms (risk vs. disease factor). One of these, 2-oxobutanoate, is part 
of the 11-metabolite predictor used for the SVM prediction model at PREOP. Enrichment analysis using the 
11-metabolite predictor revealed that 5 metabolites (N-acetyl-l-alanine, nicotinamide, Creatine, 2-oxobutanoate, 
Creatinine) are involved in metabolism of amino acids as well as 2 metabolites (Uracil, Uridine) are linked to 
pyrimidine ribonucleosides degradation. Uracil was the only metabolite linked to delirium by Guo et al.31. Dis-
ruption in amino acid metabolism has been linked to Alzheimer’s disease and  dementia46,47. Another one of these 
metabolites, N-acetyl-glutamate (NAG), is a crucial enzymatic cofactor for the first step in the urea cycle, essential 
for liver ureagenesis and reduced levels are associated with Alzheimer’s  disease48. (Supplementary Table S10).
Our systems biology approach indicates possible downregulation of the valine, leucine, isoleucine biosynthesis 
pathway at PREOP, for those patients who would go on to develop delirium following surgery. Valine, leucine, and 
isoleucine are essential branched-chain amino acids (BCAA). Essential amino acids are not naturally synthesized 
in the body and are obtained through diet. BCAAs contribute to energy production, and are key precursors in 
glutamate  synthesis49. They play critical roles in the biochemistry of the brain and are important building blocks 
in proteinogenesis. The availability of these free form amino acids is a rate-limiting step in proteinogenesis. 
BCAAs are a subset of the large neutral amino acid (LNAA) class, which also includes the aromatic amino acids 
(AAA), tyrosine, tryptophan, and phenylalanine. LNAAs are key precursors for neurotransmitters that have 
been implicated in delirium, including glutamate, serotonin, dopamine, and  norepinephrine13,14. BCAAs and 
AAAs compete for access to the central nervous system (CNS) through the large neutral amino acid transporter 
1 (LAT1)50–52. With the absence of BCAAs, there is greater opportunity for the AAAs to reach CNS and generate 
their associated neurotransmitters: serotonin, dopamine, and norepinephrine.
We identified distinct metabolites and metabolic pathophysiological pathways linked to delirium development 
at POD2. Most significantly, potential upregulation in the citrate cycle pathway in delirium cases was predicted. 
Figure 2.  Statistical approaches to discovering significant metabolites at PREOP and POD2. For (a, b), we 
applied both parametric [t-test (T)] and nonparametric [Wilcoxon Rank (W) and binomial (B)] statistical 
tests to account for the degree, direction, and rank of difference between delirium (DEL) and control (CNT) 
groups at both preoperatively (PREOP) and post-operative day 2 (POD2) time points. To correct for multiple 
hypothesis testing, we used the Benjamini–Hochberg (BH) procedure. A metabolite was considered to have 
differentially quantified concentrations if it had a BH-corrected p value < 0.05 in at least two statistical tests. (a) 
At PREOP, none of the metabolites met our strict criteria for differential concentration. Four metabolites had 
a BH-corrected p value < 0.05 only in the binomial test (see text). Systems biology was performed using the 37 
metabolites that passed two or more tests with a nominal p value < 0.05. (b) At POD2, there were 53 metabolites 
that met our criteria for differential concentration. These metabolites were used as input for systems analysis. 
Score plots for the OPLS-DA analysis using the (c) PREOP and (d) POD2 data. Ellipses represent clustering 
based on the Mahalanobis distance for outlier detection (orange: delirium, blue: control, and black: all samples). 
Metabolites with the most extreme loadings (positive and negative) for (e) PREOP and (f) POD2 are noted. 
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This is a key pathway for energy metabolism. Six metabolites within the citrate cycle (oxaloacetate, fumarate, 
citrate, aconitate, isocitrate, α-ketoglutarate) were all increased in delirium cases, as was itaconic acid, which 
is generated by decarboxylation of aconitate. Interestingly, both plasma and CSF metabolomics comparison of 
patients with Alzheimer’s disease (AD) to matched cognitive healthy controls identified a similar increase of 
several citrate cycle intermediates such as citrate, aconitate, and α-ketoglutarate in  AD53,54. Importantly, there is 
a well characterized reduction in activity of the rate limiting citrate cycle enzyme α-ketoglutarate dehydrogenase 
which converts α-ketoglutarate to succinyl-CoA55,56 that may be a key event in AD pathogenesis as well as various 
other neurodegenerative diseases due to oxidative  stress54. Reduced  α-ketoglutarate dehydrogenase may result 
in accumulation of α-ketoglutarate. A disruption of energy homeostasis and increased oxidative stress because 
of increased citrate cycle activity may be a crucial event during delirium manifestation.
Glucose is the main fuel for the brain, but under glucose-depleted conditions like strenuous exercise, fasting, 
or starvation; the ketone bodies, β-hydroxybutyrate (βOHB) and acetoacetate (AcAc), are the main alterna-
tive fuel sources. These small lipid-derived molecules are converted to acetyl-CoA and then oxidized in the 
citrate cycle to produce adenosine triphosphate and carbon  dioxide57. Kealy and colleagues showed that energy 
metabolism dysregulation was sufficiently capable of triggering an acute cognitive dysfunction in a delirium 
mouse  model44. Under normal conditions in humans, these ketones are present in plasma in an approximate 
2:1 βOHB:AcAc  ratio58. At PREOP, the delirium cohort displayed a decrease in βOHB (FC = − 1.69, nominal 
p value = 0.01), and then an upregulation of AcAc (FC = 1.54, BH p value = 0.00075) at POD2, elucidating an 
alteration in energy metabolism. At POD2 our participants were in a fasting state, which supports an increase in 
acetoacetate, but this upregulation should be uniform across both phenotypes. This disparity points to potential 
energy pathway alteration in the delirium group that is not observed in the control group. These findings support 
previous hypotheses that energy metabolism dysregulation is a possible driver in delirium  pathophysiology29,31,44.
While most of the metabolites identified in this study have not been previously linked to delirium risk or 
development, a few of these metabolites have been previously linked to inflammation, cognitive function, or 
neurological diseases. Most prominent is kynurenic acid, which our data show to be significantly increased in 
delirium cases at POD2. Kynurenic acid, a degradation product of l-tryptophan, is a neuromodulator interact-
ing with NMDA, nicotinic, and GPR35 receptors. It plays a role in various neurophysiological functions as well 
as neurological diseases and inflammatory processes. Overexpression of kynurenic acid in several neurological 
diseases is associated with  confusion58, while reduction of kynurenic acid in mice improves cognitive  function59,60. 
Both kynurenine and tryptophan are differentially quantified concentrations at POD2 in delirium samples at 
nominal, not BH-corrected, p value (< 0.05 in all three statistical tests) with kynurenine, like kynurenic acid, being 
increased and tryptophan being decreased in delirium samples. Thus, kynurenic acid may be one key metabolite 
associated with delirium development.
Despite our strengths in experimental design, established cohort, developed workflow, and data analysis 
methods, several limitations of this study are of note. The statistical power at PREOP was still insufficient to yield 
metabolites that passed two or more BH-corrected statistical tests implying the need for more samples. Second, 
the SAGES study was conducted within a single geographic region, limiting the generalizability of our results 
across other populations. Third, since only plasma samples were analyzed, it is difficult to assess whether similar 
metabolic changes occur in the brain and have functional and causal consequences with regard to delirium risk or 
development. Therefore, the identification of disruptions in several metabolic pathways and the link to delirium 
pathogenesis and pathophysiology are putative and need to be further validated. Fourth, since delirium had 
already occurred in most of our participants at the time of the POD2 blood draw, we are unable to completely 
disentangle metabolic changes that are on the causal pathway to delirium from those that result from delirium. 
Finally, targeted metabolomics is restricted by detection of the predefined metabolites established by the specific 
protocol that may result in the omission of metabolites involved in delirium.
In conclusion, we have identified metabolites associated with delirium at both pre- and post-operative time 
points that may enhance our understanding of the etiology and pathophysiology of delirium. Our findings 
highlight potential dysregulation in energy production pathways at both PREOP and POD2 paving the way for 
future studies, which should expand upon these findings through exploration of key enzymes involved in these 
pathways. The metabolomic findings at PREOP have the potential to be combined with other biomarkers to 
develop a predictive signature, which can be used to target personalized, preventative interventions to reduce 
delirium incidence. Additionally, our analysis of the metabolome at POD2 could improve our understanding 
of the disease mechanism, which may lead to better strategies to ameliorate the delirium process. Overall, the 
established workflow and data analysis provide a two-faceted approach to delirium metabolomics providing a 
comprehensive assessment of the biochemical activity associated with this syndrome.
Methods
Study participants. The Successful Aging after Elective Surgery (SAGES) study is a prospective obser-
vational study of older adults undergoing major elective non-cardiac surgery and was designed to understand 
novel risk factors and long-term outcomes of  delirium59,60. SAGES enrolled patients ≥ 70 years old scheduled for 
major noncardiac surgery, including total knee or hip replacement, cervical or lumbar laminectomy, abdominal 
aortic aneurysm repair, lower extremity vascular bypass, or colectomy. Patients received either general or spi-
nal anesthesia. Major inclusion and exclusion criteria have been  published59,60. Patients underwent a detailed 
screening process to exclude dementia based on medical record review, capacity assessment, patient or family 
report of dementia diagnosis, and cognitive testing using the Modified Mini-Mental State  Examination61. In 
addition, patients underwent a neurocognitive battery at baseline, which was used to compute the general cog-
nitive performance (GCP) summary  measure62. Comorbidities were identified from medical record review by 
trained physician abstractors and scored based on the Charlson Comorbidity Index.
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Informed consent for study participation was obtained from all subjects according to procedures approved 
by the institutional review boards of Beth Israel Deaconess Medical Center (BIDMC) and Brigham and Women’s 
Hospital, the two surgical sites, and Hebrew SeniorLife, the study coordinating center, all located in Boston, 
Massachusetts. All experiments, methods, and analyses conducted in the current manuscript were performed 
in accordance with relevant guidelines and regulations of the institutional review board (IRB) of all participat-
ing institutions.
Data collection. Postoperative delirium was determined daily throughout hospitalization, supplemented 
with a validated chart review to identify cases that may have been missed during daily interviews. Delirium was 
assessed using the Confusion Assessment Method (CAM) diagnostic  algorithm63,64. The presence of delirium by 
chart review was adjudicated by at least two delirium experts, and discordance was resolved through  consensus65. 
Patients were considered delirious if delirium was present on either the CAM or the chart review method on any 
postoperative day; otherwise, patients were considered non-delirious. If delirium was absent during the entire 
hospitalization, subsyndromal delirium was defined as (i) an acute change in mental status or fluctuation, (ii) at 
least one CAM core feature (inattention, disorganized thinking, altered level of consciousness), and (iii) at least 
one other CAM supporting feature (disorientation, perceptual disturbance, delusion, psychomotor agitation, 
psychomotor retardation, or inappropriate behavior)66.
Creation of nested matched case-control sample. From the entire SAGES cohort, a matched delir-
ium/no-delirium sample was previously identified to examine inflammatory markers and plasma  proteomics67,68. 
Delirium cases (DEL) were defined as patients with delirium on POD2. No delirium controls (CNT) were 
defined as patients with no delirium or no subsyndromal delirium during their hospital stay. DEL/CNT pairs 
were matched on six variables (age and baseline GCP within five years, and an exact match for sex, presence of 
vascular comorbidity, surgery type, and Apolipoprotein E [APOE] ε4 status) (Table 1). Vascular comorbidity 
was present if the participant had at least one Charlson diagnosis related to vascular disease: myocardial infarc-
tion, congestive heart failure, peripheral vascular disease, cerebrovascular disease, hemiplegia, and diabetes or 
diabetes with end organ damage. For APOE genotype, DNA was extracted from cellular material in the blood 
and genotyped at the Partners Center for Personalized Medicine. Patients with at least one ɛ4 allele were defined 
as APOE ɛ4 carriers. To limit heterogeneity of surgical procedure only patients who underwent an orthopedic 
procedure were included in this manuscript 66 matched pairs. Fourteen pairs with low plasma volume in the 
biorepository were excluded, yielding n = 52 matched pairs (104 participants) for inclusion in this study.
Blood collection and processing for plasma. Heparinized plasma samples were collected and stored 
as part of the SAGES  study59 as previously  described68. PREOP and POD2 timepoint plasma was utilized in 
the present study. For all of the samples, blood was collected in a non-fasting state at PREOP and in a fasting 
state at POD2. A pooled control sample was created from twenty PREOP samples (ten males and ten females) 
from patients de-enrolled from the SAGES study. Metabolites were extracted from equal volumes of heparinized 
plasma (100 µl) by ice-cold methanol precipitation added to a final concentration of 80% (vol/vol).
Targeted metabolomics. Equal volumes per sample of methanol extracted metabolites were run on a 
5500 QTRAP (SCIEX, Framingham, MA) mass spectrometer using a previously published targeted method-
ology developed by the BIDMC Mass Spectrometry  Core69. This protocol utilizes a targeted selected reaction 
monitoring (SRM), positive/negative ion-switching, mass spectrometry-based metabolomics platform suitable 
for bodily fluids, cells, and fresh and fixed  tissue69.
Description of data. To accommodate for the maximum sample loading capacity of the 5500 QTRAP 
60 samples, six unique sample preps and mass spectrometry runs were performed for a total of 52 matched 
DEL/CNT pairs at PREOP and POD2 that resulted in analysis of a total of 208 samples. Each experimental 
run—except for the final one, which was abridged due to sample limitations—included ten matched pairs, three 
internal spike-in standards, thirteen pooled quality control plasma samples (QC), three conditioning samples 
and four blanks (Fig. 1, Supplementary Fig. S1). In the supplementary material we explain the sample order for 
each run, in detail.
Preprocessing of metabolomics data. Overall, 315 metabolites were measured using previously published 
targeted methodology (Supplementary Table S1)69. A metabolite was considered “present” if it was measured in at 
least 50% of the samples within a phenotypic group (PREOP CNT, PREOP DEL, POD2 CNT, POD2 DEL).
Signal drift was corrected with statTarget using a quality control-based machine learning algorithm: random 
forest signal correction (QC-RFSC)70,71. This allowed for the integration of the six different experimental runs 
using the pooled QC samples. Metabolites deemed absent were omitted while signal imputation was performed 
on the remaining using the k-nearest neighbor (knn)  method72.
NormalizeMets R package was used to normalize the metabolomics data matrix to previously selected internal 
standards using the NOMIS: normalization using optimal selection of multiple internal standards  technique71,73,74.
Statistical analysis. Differential metabolite concentration was assessed using both parametric and nonpar-
ametric statistical tests to account for the degree, direction, and rank of difference between DEL and CNT groups 
at both PREOP and POD2 time points. For all statistical tests (paired t-test, binomial test, and Wilcoxon signed-
rank test), the Benjamini–Hochberg (BH) procedure was applied to correct for multiple hypotheses  testing75. 
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These results were further tested for robustness using tenfold split analysis at a 5% significance level, with 80% 
power, and run 10,000 times (Supplementary Table S6). If a metabolite came up as significant in the majority of 
the splits (≥ 50%), this conferred a level of confidence in the observed differential concentration. Fold-change 
(FC) of metabolite concentration was calculated by applying the one-step Tukey’s biweight algorithm on FC val-
ues (DEL/CNT) for each paired  sample76. This provides a robust estimation of the FC for each individual metab-
Figure 3.  Pathway analysis of metabolites with significant differentially quantified concentrations using 
 MetaboAnalyst81–83. Red indicates upregulation in DEL and green denotes downregulation. Grey represents 
metabolites not included in our targeted metabolomics protocol. Superscripts signify direction of change for 
the metabolites that did not exhibit significant differential concentrations. The +, −, and × superscripts indicate 
upregulated (in DEL), downregulated (in DEL), and signal too low or not present, respectively. (a) At PREOP, 
the valine, leucine, and isoleucine biosynthesis pathway was the only one with metabolites with significantly 
differentially quantified concentrations (FDR < 0.04). Dashed boxes represent the reactions that are specific to 
human. (b) At POD2, the citrate cycle pathway was the most significantly enriched.
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olite that is unaffected by outliers. The FCs of the metabolites that are downregulated in the delirium group are 
indicated using the negative sign, e.g., a FC of − 2 implies two-fold downregulation in the delirium group.
Multivariate statistical analysis was performed using the ropls package in the statistical program  R71,77. 
Potential outliers were identified using principal component analysis (PCA) and Mahalanobis  distance78 and 
were omitted prior to the application of orthogonal partial least squares-discriminant analysis (OPLS-DA), a 
supervised multivariate separation  method77,79. The model was validated through sevenfold cross-validation, 
cross validation-analysis of variance (CV-ANOVA)80, and response permutation testing (n = 1000) using the fit 
metrics R2X, R2Y, and Q2.
Systems biology analysis. Systems biology analyses of delirium-related metabolites were performed using 
MetaboAnalyst 4.0 (Montreal, Quebec, Canada)81–83, which takes a bifurcated analytic approach that includes 
metabolite over-representation and pathway  topology41,84. A metabolite was included in biological systems 
analysis if it showed significant differential concentration (nominal p value < 0.05 (PREOP), BH p value < 0.05 
(POD2)) in two or more statistical tests. At PREOP, nominal p value was used in lieu of BH p value because sys-
tems analysis requires more metabolites than those that met the BH significance cut-off < 0.05.
Hypergeometric testing was used to assess if delirium-related metabolites were overrepresented in a pathway 
more than expected by  chance81,82. A pathway was considered enriched if the false discovery rate (FDR) adjusted 
p value was < 0.05. In topology analysis, perturbed metabolites located in critical or central positions are deemed 
to have a greater impact on a pathway.
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Figure S1: Run sample order: The injection order and sample type for each analytical run 
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Sample distribution for each of the six runs 
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Two matched pairs in Run6 were repeats from Run1 and were removed following preprocessing and prior to downstream analysis 
 
                                                                                                        
 52 matched pairs for 208 samples 
 
The injection order was specifically designed to combine multiple analytical runs while controlling for peak drift and internal and external 
noise. The blank and conditioning samples were used to minimize carryover from previous samples and identify background noise. The 






Figure S2: ROC1 curve for SVM2 prediction model using 11-metabolite predictors at PREOP3 
  
1Receiver operating characteristic, 2support vector machine, 3Preoperative 
The eleven predictor metabolites used included: uracil, proline, 3-hydroxybuterate, trehalose-6-phosphate, N-acetyl-L-alanine, creatine, 




Figure S3: Significant Pathways using MetaboAnalyst and KEGG pathways [1-6] 
a  Valine, Leucine, Isoleucine Biosynthesis 
 




c Pyrimidine Metabolism 
 




e Cysteine and Methionine Metabolism
 
f Pentose Phosphate Pathway 
  
Red denotes those metabolites found to be significant between delirium and control groups. Top three pathways enriched with 
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